×
0 0 0 0 -0.00273722627737237 -0.0885036496350365 -0.0894160583941606 -0.11588503649635
Stockreport

MediNova's MN-166 reduced progression of MS by 26% in mid-stage study [Seeking Alpha]

MEDICINOVA (MNOV)  More Company Research Source: Seeking Alpha
Last medicinova earnings: 4/25 04:16 pm Check Earnings Report
US:NASDAQ Investor Relations: medicinova.com/investor-relations/media-archive
PDF MediNova's MN-166 reduced progression of MS by 26% in mid-stage studyMediciNova's (NASDAQ:MNOV) lead candidate MN-166 (ibudilast) demonstrated atreatment effect in a Phase 2b clinical trial. The results were presented at the ACTRIMS conference in San Diego, CA.Data from the study, called SPRINT-MS, showed treatment with MN-166 reduced the risk of confirmed disability progression by 26% (hazard ratio = 0.74) versus placebo in patients with progressive multiple sclerosis (MS).The study achieved both primary endpoints. MN-166 produced a statistically significant 48% reduction in the rate of progression of whole brain atrophy compared to placebo (p=0.04) as measured by MRI and it demonstrated a favorable safety and tolerability profile. There was no statistically significant difference in tolerability between MN-166 and placebo.The most common treatment-emergent adverse events were gastrointestinal in nature and occurred at a higher rate in the MN-166 cohort. Upper respiratory infections [Read more]

IMPACT SNAPSHOT EVENT TIME: MNOV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS